...
首页> 外文期刊>Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology >Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
【24h】

Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.

机译:非CB1,用于内胆碱蛋白,植物大麻素和合成大麻素的非CB2受体:聚焦在G蛋白偶联的受体和瞬态受体电位通道上。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The molecular mechanism of action of Delta(9)-tetrahydrocannabinol (THC), the psychotropic constituent of Cannabis, has been a puzzle during the three decades separating its characterization, in 1964, and the cloning, in the 1990s, of cannabinoid CB1 and CB2 receptors. However, while these latter proteins do mediate most of the pharmacological actions of THC, they do not seem to act as receptors for other plant cannabinoids (phytocannabinoids), nor are they the unique targets of the endogenous lipids that were originally identified in animals as agonists of CB1 and CB2 receptors, and named endocannabinoids. Over the last decade, several potential alternative receptors for phytocannabinoids, endocannabinoids, and even synthetic cannabimimetics, have been proposed, often based uniquely on pharmacological evidence obtained in vitro. In particular, the endocannabinoid anandamide, and the other most abundant Cannabis constituent, cannabidiol, seem to be the most "promiscuous" of these compounds. In this article, we review the latest data on the non-CB1, non-CB2 receptors suggested so far for endocannabinoids and plant or synthetic cannabinoids, and lay special emphasis on uncharacterized or orphan G-protein-coupled receptors as well as on transient receptor potential channels.
机译:Delta(9)-taThydnabinol(THC)的分子机制,大麻的精神组成,在三十年中,在1964年,在1990年代,大麻素CB1和CB2中的克隆是一种难题受体。然而,虽然后一种蛋白质确实介导THC的大部分药理作用,但它们似乎并不担对于其他植物大麻素(植物植物植物)的受体,也不是它们是最初在动物中作为激动剂鉴定的内源性脂质的独特靶标CB1和CB2受体,并命名为内胆蛋白。在过去的十年中,已经提出了几个用于植物植物植物,环诺蛋白,甚至合成大麻纤维素的若干潜在的替代受体,通常是唯一的关于体外获得的药理学证据。特别地,内胆胆糖醛胺,以及其他最丰富的大麻组分,大麻似乎是这些化合物的最“混杂性”。在本文中,我们在迄今为止的非CB1的非CB1上的最新数据,以迄今为止的内凸吲哚组蛋白和植物或合成大麻素,并特别强调在非特征或孤儿G蛋白偶联的受体以及短暂受体上潜在渠道。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号